Kamalakar Chatla
Technical Development Principal Scientist Genentech
Kamalakar Chatla is a Technical Development Principal Scientist at Genentech, where he supports Cell and Gene Therapy programs through advanced analytical characterization strategies. His work focuses on developing and implementing innovative analytical methods to enhance product understanding, define critical quality attributes, and drive product and process improvement across development stages. He has expertise in analytical development for RNA and gene-editing therapeutics, with particular emphasis on orthogonal method evaluation, multi-attribute analytical platforms, and establishing correlations between molecular quality attributes and functional performance. His work aims to strengthen manufacturing control strategies and enable data-driven decision-making within CMC environments for next-generation cell and gene therapies.
Seminars
- Consolidation & Operational Efficiency: NGS is a robust, single-platform Multi-Attribute Method (MAM), capable of consolidating USP-recommended CQAs including Identity, Integrity, 5, Capping, and Poly(A) tail length into a single 4–8-hour workflow. By replacing fragmented, low-throughput orthogonal assays (CGE, HPLC, and MS), this approach significantly reduces analytical burden and operational complexity in CMC environments
- Superior Resolution through Single-Molecule Depth: NGS provides enhanced molecular resolution over bulk-averaging methods, resolving complex poly(A) heterogeneity and 5, truncations with >99%sequence accuracy
- Direct Impurity Traceability: NGS can traced a minor deletion from the mRNA product back to the synthetic DNA template
